Sepsis research: We must change course

Critical Care Medicine

Volumn 27, Issue 2, 1999, Pages 427-430

  Nasraway Jr , Stanley A ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CENTOXIN; ENDOTOXIN ANTIBODY; IMMUNOMODULATING AGENT; N(G) METHYLARGININE; TAUROLIDINE; TENEFUSE; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CASE FINDING; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG FATALITY; DRUG RESEARCH; DRUG SCREENING; GRAM NEGATIVE SEPSIS; HUMAN; METHODOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0032962833     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199902000-00054     Document Type: Review

References (46)

1. 1. Fisher CJ, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor:fc fusion protein. N Engl J Med 1996; 334: 1697-1702
2. 2. McCloskey RV, Straube RC, Sanders C, et al: Treatment of septic shock with human monoclonal antibody HA-1A. Ann Intern Med 1994; 121:1-5
3. 3. Zeni F, Freeman B, Natanson C: Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997; 25:1095-1100
4. 4. Opal SM, Fisher CJ Jr, Dhainaut J-FA, et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25:1115-1124
5. 5. Fisher CJ, Dhainaut JFA, Opal SM: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 1994; 271:1836-1843
6. 6. Rodell TC, Foster C: Sepsis data show negative trend in second phase II sepsis trial. July 18, 1995. Press Release. Cortech, Denver, CO
7. 7. Fein AM, Bernard Gr, Griner GJ, et al: Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, Deltibrant (CP-0127). JAMA 1997; 277: 482-487
8. 8. Dhainaut, JFA, Tenaillon A, LeTuizo Y: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994; 22:1720-1728
9. 9. Dhainaut JFA, Tenaillon A, Hemmer M: Confirming phase III clinical trial to study the efficacy of a PAF antagonist, BN 52021, in reducing mortality of patients with severe Gram-negative sepsis. Abstr. Am J Respir Crit Care Med 1995; 151-A447
10. 10. Kay CA: Can better measures of cytokine responses be obtained to guide cytokine inhibition? Knoll AG, Ludwigshafen, Germany. Presentation and handout. Cambridge Health Institutes' Designing Better Drugs & Clinical Trials for Sepsis/SIRS: Reducing Mortality to Patients and Suppliers. Washington, DC, February 20-21, 1996 (Unpub)
11. 11. Reinhart K, Wiegand-Lohnert C, Grimminger F: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody fragment, MAK 195, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose ranging study. Crit Care Med 1996; 24:733-742
12. 12. Fisher CJ, Opal SM, Dhainaut JF: Influence of anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21:318-327
13. 13. Dhainaut JFA, Vincent JL, Richard C: CDP571, a humanized antibody to human tumor necrosis factor-alpha: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. Crit Care Med 1995; 23:1461-1469
14. 14. Abraham E, Wunderink R, Silverman H: Efficacy and safety of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis syndrome. JAMA 1995; 273:934-941
15. 15. Cohen J, Carlet J: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24:1431-1440
16. 16. Abraham E, Glauser MP, Butler T, et al: P55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. JAMA 1997; 277:1531-1538
17. 17. Bernard GB, Wheeler AP, Russell JA, et al: The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997; 336: 912-918
18. 18. Haupt MT, Jastremski MS, Clemmer TP, et al: Effect of ibuprofen in patients with severe sepsis: A randomized, double-blind, multicenter study. Crit Care Med 1991; 19:1339-1347
19. 2 formation is increased in human sepsis syndrome. Am Rev Respir Dis 1991; 144:1095-1101
20. 20. Fisher CJ, Slotman CJ, Opal SM: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22:12-21
21. th International Symposium on Intensive Care and Emergency Medicine, Brussels, March 17, 1998
22. 22. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998; 351: 929-933
23. 23. Abraham E: The 1998 International Conference. Chicago, April 24, 1998
24. 24. Ziegler EJ, Fisher CJ, Sprung CL, et al: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A sepsis study group. N Engl J Med 1991; 324:429-436
25. 25. Greenman RL, Schein RMH, Martin MA, et al: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gramnegative sepsis. JAMA 1991; 266: 1097-1102
26. 26. Bone RC, Balk RA, Fein AM, et al: A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, muticenter, randomized, controlled trial. Crit Care Med 1995; 23:994-1006
27. 27. Vincent JL: Search for effective immunomodulating strategies against sepsis. Lancet 1998; 351:922-923
28. 28. Fink MP: Another negative clinical trial of a new agent for the treatment of sepsis: Rethinking the process of developing adjuvant treatments for serious infections. Crit Care Med 1995; 23:989-991
29. 29. Pastores SM, Hasko G, Vizi S, et al: Cytokine production and it manipulation by vasoactive drugs. New Horiz 1996; 4:252-264
30. 30. Galley HF, Nelson SJ, Dubbels AM, et al: Effect of ciprofloxacin on the accumulation of interleukin-6, interleukin-8, and nitrite from a human endothelial cell model of sepsis. Crit Care Med 1997; 25:1392-1395
31. 31. Tremblay L, Valenza F, Ribeiro SP, et al: Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. J Clin Invest 1997; 99:944-952
32. 32. Casey L: Antibiotics: More than just "bug" killers. Crit Care Med 1997; 25:1270-1271
33. 33. Vincent JL: Dear SIRS, I'm sorry that I don't like you. Crit Care Med 1997; 25:372-372
34. 34. Bone RC: Sepsis and controlled clinical trials: The odyssey continues. Crit Care Med 1995; 23:1313-1315
35. 35. Luce J: Reducing the use of mechanical ventilation. N Engl J Med 1996; 335:1916-1917
36. 36. Slutsky AS: Mechanical ventilation: American College of Chest Physicians' Consensus Conference. Chest 1993; 104:1833-1859. Erratum, Chest 1994; 106:656
37. 36. Slutsky AS: Mechanical ventilation: American College of Chest Physicians' Consensus Conference. Chest 1993; 104:1833-1859. Erratum, Chest 1994; 106:656
38. 37. Hollenberg SM, Ahrens TS, Astiz ME, et al: Practice parameters for hemodynamic support in sepsis. Crit Care Med, In Press
39. 38. Tissue oxygenation in acute medicine: Roundtable Conference. Brussels, March 14, 1998
40. 39. Hayes MA, Timmins AC, Yau EHS, et al: Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330: 1717-1722
41. 40. Members of the ACCP/SCCM Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies for sepsis. Crit Care Med 1992; 20:864-874
42. 41. Muckart DJJ, Bhagwanjee S: ACCP/ SCCM consensus conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med 1997; 25:1789-1795
43. 42. Bossink AWJ, Groeneveld ABJ, Hack CE, et al: Prediction of mortality in febrile medical patients. How useful are systemic inflammatory response syndrome and sepsis criteria? Chest 1998; 113:1533-1541
44. 43. Opal SM. The uncertain value of the definition for SIRS. Chest 1998; 113:1442-1443
45. 44. Blumenthal D, Epstein AM: The role of physicians in the future of quality management. N Engl J Med 1996; 335:1328-1331
46. 2 removal for adult respiratory distress syndrome. Am J Respir Crit Care Med 1994; 149:295-305